Ong Sin Tiong

 

RESEARCH

The research themes of this laboratory are translational in nature, and centre on gaining a better understanding of the mechanisms which give rise to cancer drug resistance, and defining novel therapeutic strategies to overcome drug resistance.

Selected Publications

• Cherian J, Nacro K, Poh ZY, Guo S, Jeyaraj DA, Wong YX, Ho M, Yang HY, Joy JK, Kwek ZP, Liu B, Wee JLK, Ong EHQ, Choong ML, Poulsen A, Lee MA, Pendharkar V, Ding LJ, Manoharan V, Chew YS, Sangthongpitag K, Lim S, Ong ST, Hill J, and Keller TH. Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. J. Med. Chem., 59 (7), 3063–3078 (2016). [PMID27011159] Abstract
• Tanimoto A, Takeuchi S, Arai S, Fukuda K, Yamada T, Roca X, Ong ST, Yano S. Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib-resistance in EGFR-mutant lung cancer. Clin Can Res 2016. [PMID27986747] Abstract
• Soh, S.X., et al., with Ong ST as senior author. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia. PLoS One 9, e103435 (2014). [PMID25090024] Abstract
• Juan, W.C., Roca, X. & Ong, S.T. Identification of cis-acting elements and splicing factors involved in the regulation of BIM Pre-mRNA splicing. PLoS One 9, e95210 (2014). [PMID24743263] Abstract
• Ng KP, Manjeri A, Lee KL, Huang W, Tan SY, Chuah CT, Poellinger L, Ong ST. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood 123, 3316-3326 (2014). [PMID24705490] Abstract
• Lim S, Saw TY, Zhang M, Janes MR, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CTH, and Ong ST. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci USA,18;110(25):E2298-307 (2013). [PMID 23737503] Abstract
• Ng et al. (55 authors), with ONG ST as senior and corresponding author. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine, 18: 521-528 (2012). [PMID22426421] Abstract
• Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine, 16: 205–213 (2010). [PMID20072130] Abstract
• Zhang M, Fu W, Prabhu S, Trapp V, Ko J, Moore JM, Kim JW, Druker BJ, Fruehauf J, Gram H, Fan HY, Ong ST. Inhibition of Polysome Assembly Enhances Imatinib Activity Against Chronic Myelogenous Leukemia, and Overcomes Imatinib Resistance. Molecular and Cellular Biology, 28: 6496-6509 (2008). [PMID18694961] Abstract
• Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via mTOR. Cancer Research,63: 5716-5722 (2003). [PMID14522890] Abstract